Alxoid

Allergoid Immunotherapy Product

Alxoid is an allergoid immunotherapy product developed in Europe for use in subcutaneous immunotherapy (SCIT). It is chemically modified to reduce allergenicity while maintaining the capacity to stimulate protective immune responses. This modification is designed to offer a safer initial desensitisation experience for patients with environmental allergies such as dust mites or grass pollens.

Overview

Alxoid may be used as part of a single-allergen or multi-allergen treatment plan, providing flexibility for clinicians tailoring therapy to individual patient sensitivities.

It is delivered exclusively under the supervision of a trained allergy clinician in a controlled medical setting, following build-up and maintenance protocols consistent with best practice SCIT guidelines.

Safety Profile

Safety profile

Alxoid offers a lower risk of systemic allergic reactions compared with native allergen extracts.

Common side effects include:

Mild local swelling or redness at the injection site

Temporary itching or discomfort

Rare systemic reactions, managed with standard emergency procedures in the clinic

Effectiveness

Clinical studies indicate that Alxoid is effective in improving symptoms of environmental allergies and reducing the need for medication.

While immune response and symptom reduction may take several months to become noticeable, many patients experience significant improvement over a 3–5 year treatment course.

3–5 year treatment course

It is delivered exclusively under the supervision of a trained allergy clinician in a controlled medical setting.

Treatment options

Single allergen therapy

Single allergen therapy:

Focused on one allergen, such as dust mite or grass pollen, for targeted desensitisation.

Multi-allergen therapy

Multi-allergen therapy:

Combines multiple allergens in one preparation, allowing treatment of patients sensitised to more than one trigger.

Alxoid’s allergoid formulation allows combination while maintaining a favourable safety profile.

Both TGA-registered and non-registered options exist.

Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.

Administration

Administered via subcutaneous injection in clinic

Initial build-up phase with gradual dose increases

Maintenance phase involves less frequent injections for sustained desensitisation

Requires patient monitoring for potential adverse reactions

Patient Suitability

Patient suitability

Alxoid may be appropriate for patients who:

Have confirmed IgE-mediated allergies to environmental allergens

Are considered at higher risk of reactions with native extracts

Prefer SCIT and can attend clinic-based treatments

Seek a structured, clinically supervised immunotherapy program

Australian Context

Australian context

Not PBS-subsidised; treatment is privately funded

TGA-registered or non-registered depending on product specifics

Part of a personalised allergen immunotherapy plan supervised by a clinician

Conclusion

Alxoid is a versatile and well-tolerated allergoid SCIT product, offering patients a safer pathway to allergen desensitisation.

It balances safety and efficacy while allowing flexible treatment for single or multiple allergens.

Its design is particularly suitable for patients who require careful initial desensitisation due to higher sensitivity, supporting gradual and controlled improvement in allergy symptoms over time.